Recent Advances in the Treatment and Management of Chronic Lymphocytic Leukemia (CLL): Expert Perspectives on the Evolving Role of BTK Inhibitors and Combination Therapy is a three part webinar series

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Chronic Lymphocytic Leukemia (CLL)

These are archives of live webinars held between March 10, 2021 to March 19, 2021
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

These activities are valid from April 1, 2021 to April 1, 2023

This series is supported by an educational grant from
AstraZeneca

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2021, it is expected that there will be 20,720 new cases of CLL and about 3,930 deaths. Fortunately for patients with CLL, several new treatments have recently become available, including BTK inhibitors, giving healthcare professionals many new options to improve patient outcomes with these new treatments and strategies.

A Closer Look at Recent Data and Guideline Updates in CLL: Expert Perspectives on the Evolving Role of BTK Inhibitors and Combination Therapy

1. Examine the clinical burden of chronic lymphocytic leukemia (CLL), including factors that contribute to poor prognosis and increased costs
2. Explore recent clinical data regarding mechanistic activity, efficacy, and safety of approved and emerging therapeutic options, and combination therapy, for chronic lymphocytic leukemia (CLL)
3. Evaluate the evolving role of next generation BTK inhibitors, and their combinations, in the first-line management of CLL
4. Compare and contrast BTK inhibitors, and their combinations, in the management of CLL, including their pharmacological difference

Comparative Effectiveness and Payer-Provider Coordination in CLL: What Does Managed Care Need to Know About New and Emerging Combinations Therapies?

1. Examine the economic burden of chronic lymphocytic leukemia (CLL), including factors that contribute to poor prognosis and increased costs
2. Evaluate managed care considerations on optimizing the use of BTK inhibitors, and their combinations, in CLL, managing therapy-related toxicities, improving adherence, expanding payer/provider communication, and aiding in the implementation of clinical pathways to deliver quality care
3. Describe approaches currently utilized by third party payers to manage costs associated with the care of patients with CLL
4. Assess the managed care considerations of newer, second generation BTK inhibitors, and their combinations, by exploring where these agents fit in the evolving CLL treatment paradigm
5. Transform therapeutic advances and resource utilization data on BTK inhibitors, and their combinations, in CLL into informed health plan decisions

Improving Patient Adherence and Quality of Life in CLL: Strategies for Anticipating, Recognizing,
and Managing Adverse Events in BTK Inhibitors and Combination Therapy

1. Explore challenges to patient adherence and quality of life in the management of CLL
2. Discuss strategies to continue the implementation of BTK inhibitors and their combinations into the treatment paradigm, especially as it relates to patient adherence and quality of life
3. Compare and contrast the varying adverse events that are associated with the use of BTK inhibitors, and their combinations, in CLL
4. Formulate effective strategies for ensuring the proper selection and use of BTK inhibitors in the care of individual CLL patients and patient populations